Welcome to our dedicated page for Beyond Air SEC filings (Ticker: XAIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Beyond Air, Inc. (NASDAQ: XAIR) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, giving investors structured access to official information about this commercial-stage medical device and biopharmaceutical issuer. Beyond Air develops nitric oxide (NO) generators and delivery systems, including the LungFit platform, and pursues NO-based therapeutics in respiratory, neurological, and oncology indications. Its filings provide detailed context on these activities.
Core documents such as annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) typically describe the LungFit PH system, its FDA approval and CE Mark for neonatal hypoxic respiratory failure associated with pulmonary hypertension, the broader LungFit pipeline for severe lung infections, and affiliated programs like Beyond Cancer’s ultra-high concentration NO for solid tumors and NeuroNOS’s small-molecule nNOS inhibitors. Risk factors, R&D narratives, and segment information in these reports help readers understand the company’s NO-focused strategy and development stage.
Current reports on Form 8-K capture material events, including financing agreements such as promissory notes and equity purchase arrangements, warrant inducement transactions, reverse stock split implementation, leadership changes, and transactions involving subsidiaries like NeuroNOS. Registration statements, including Forms S-1 or S-3, outline the terms of securities offerings, equity lines of credit, and resale arrangements for investors like Streeterville Capital.
On this page, Stock Titan supplements raw filings data with AI-powered summaries that highlight key terms, financial obligations, and business implications from lengthy documents. Users can quickly identify items related to capital structure changes, Orphan Drug Designations, or regulatory milestones without reading every page. Real-time updates from EDGAR, combined with structured access to Forms 4 and other ownership reports, allow close monitoring of insider and institutional activity in XAIR. This makes the filings page a practical starting point for due diligence on Beyond Air’s regulatory, financial, and clinical disclosure record.
Beyond Air (NASDAQ: XAIR) filed its Form 10-K Annual Report on June 29, 2025. The excerpt supplied consists almost entirely of XBRL taxonomy tags and entity identifiers, with no accompanying financial statements, narrative sections, risk factors, legal proceedings, or management discussion. Because the critical quantitative and qualitative disclosures normally included in a 10-K are absent from the provided content, no material information relevant to investors can be summarized from this excerpt.
Beyond Air (NASDAQ: XAIR) reported several significant developments in this 8-K filing:
Key Events:
- Released financial results for fiscal quarter and year ended March 31, 2025 (detailed results not provided in filing)
- Appointed Robert Goodman to Board of Directors on June 16, 2025 - Qualified as independent director under Nasdaq standards - Notable experience with BioTelemetry, Philips Healthcare, Cardiocore, Thermo Fisher Scientific, and Pfizer
- Submitted PMA supplement application to FDA for LungFit PH II, their next-generation therapeutic nitric oxide generator
The company filed two press releases as exhibits (99.1 and 99.2) detailing the financial results and FDA submission respectively. The appointment of Goodman strengthens the board with extensive healthcare industry expertise, while the FDA submission represents a significant regulatory milestone for their therapeutic device development program.